Guardant Health ECLIPSE blood test shows 83% sensitivity for colorectal cancer in 20,000+ patient study

Guardant Health, Inc.

ECLIPSE study: 83% sensitivity for CRC detection, 90% specificity vs. negative colonoscopy.
Advanced adenoma sensitivity at 13%; cfDNA-only test outperformed cfDNA+protein version.
Plans PMA submission to FDA in Q1 2023; results exceed CMS reimbursement criteria.
Blood test completion rate 90% vs. 43-66% for stool tests; aims to address 49M unscreened adults.
Guardant expands test to other cancers including lung cancer; co-CEO cites breakthrough in blood-based screening.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.